506149
p53 Activator III, RITA
The p53 Activator III, RITA, also referenced under CAS 213261-59-7, modulates the biological activity of p53. This small molecule/inhibitor is primarily used for Activators/Inducers applications.
别名:
p53 Activator III, RITA, NSC 652287, 2,5- bis-(5-Hydroxymethyl-2-thienyl)-furan, Reactivation of p53 and Induction of Tumor cell Apoptosis, MDM2 Antagonist VII, MDM2 Inhibitor X
登录查看公司和协议定价
所有图片(1)
About This Item
推荐产品
品質等級
化驗
≥97% (HPLC)
形狀
crystalline solid
製造商/商標名
Calbiochem®
儲存條件
OK to freeze
protect from light
溶解度
ethanol: 1 mg/mL
DMSO: 3 mg/mL
運輸包裝
ambient
儲存溫度
2-8°C
InChI
1S/C14H12O3S2/c15-7-9-1-5-13(18-9)11-3-4-12(17-11)14-6-2-10(8-16)19-14/h1-6,15-16H,7-8H2
InChI 密鑰
KZENBFUSKMWCJF-UHFFFAOYSA-N
一般說明
A cell-permeable, p53-targeting, tricyclic thiophene derivative that displays antitumor properties. Blocks p53—MDM2 interaction and p53 ubiquitination and induces p53-dependent apoptosis in tumor cells expressing wild-type p53. Shown to restore the tumor suppressor function of p53 by inducing its accumulation in HCT116 colon carcinoma cells (~0.1 µM) and in p53-positive SCID mice xenografted with HCT116 cells (0.1, 1 or 10 mg/kg, ip) in vivo.
A cell-permeable, p53-targeting, tricyclic thiophene derivative that displays antitumor properties. Blocks p53—MDM2 interaction and p53 ubiquitination and induces p53-dependent apoptosis in tumor cells expressing wild-type p53. Shown to restore the tumor suppressor function of p53 by inducing its accumulation in HCT116 colon carcinoma cells (~0.1 µM) and in p53-positive SCID mice xenografted with HCT116 cells (0.1, 1 or 10 mg/kg, ip) in vivo.
生化/生理作用
Cell permeable: yes
Primary Target
p53
p53
Product does not compete with ATP.
Reversible: no
包裝
Packaged under inert gas
警告
Toxicity: Irritant (B)
重構
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
其他說明
Grinkevich, V., et al. 2005. Nat. Med.11, 1136.
Krajewski, M., et al. 2005. Nat. Med.11, 1135.
Issaeva, N., et al. 2004. Nat. Med.10, 1321.
Nieves-Neira, W., et al. 1999. Mol. Pharmacol.56, 478.
Rivera, M.I., et al. 1999. Biochem. Pharmacol.57, 1283.
Krajewski, M., et al. 2005. Nat. Med.11, 1135.
Issaeva, N., et al. 2004. Nat. Med.10, 1321.
Nieves-Neira, W., et al. 1999. Mol. Pharmacol.56, 478.
Rivera, M.I., et al. 1999. Biochem. Pharmacol.57, 1283.
法律資訊
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
儲存類別代碼
11 - Combustible Solids
水污染物質分類(WGK)
WGK 1
閃點(°F)
Not applicable
閃點(°C)
Not applicable
International journal of biological sciences, 17(9), 2367-2379 (2021-07-10)
Recombinant human bone morphogenetic proteins (rhBMPs) can stimulate bone formation and growth in the treatment of spinal fusions and nonunions. However, it is still unclear whether rhBMPs function in the prevention of intervertebral disc degeneration (IDD). Here, we discovered that
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门